Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (atsiveria naujas langas)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Šaltinis‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Kodas‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (atsiveria naujas langas)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (atsiveria naujas langas)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Šaltinis‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Kodas‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (atsiveria naujas langas)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (atsiveria naujas langas)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Šaltinis‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Kodas‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (atsiveria naujas langas)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (atsiveria naujas langas)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Šaltinis‎: Blood 2003;102(4):1529-30.

Kodas‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (atsiveria naujas langas)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (atsiveria naujas langas)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Šaltinis‎: Transfusion 2007;47(10):1830-6.

Kodas‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (atsiveria naujas langas)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (atsiveria naujas langas)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Šaltinis‎: Iran J Blood Cancer 2009;1(4):147-50.

Kodas‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (atsiveria naujas langas)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (atsiveria naujas langas)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Šaltinis‎: Int J Hematol 2012;95(1):51-6.

Kodas‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (atsiveria naujas langas)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (atsiveria naujas langas)

Perrine SP.

Šaltinis‎: Pediatr Ann 2008;37(5):339-46.

Kodas‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (atsiveria naujas langas)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (atsiveria naujas langas)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Šaltinis‎: Sci Rep. 2022;12(1):2752.

Kodas‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (atsiveria naujas langas)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (atsiveria naujas langas)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Šaltinis‎: Haematologica 2004;89(10):1172-8.

Kodas‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (atsiveria naujas langas)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (atsiveria naujas langas)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Šaltinis‎: Arch Iran Med 2009;12(3):295-7.

Kodas‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (atsiveria naujas langas)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (atsiveria naujas langas)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Šaltinis‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Kodas‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (atsiveria naujas langas)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (atsiveria naujas langas)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Šaltinis‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Kodas‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (atsiveria naujas langas)

Fetal globin gene inducers: novel agents and new potential. (atsiveria naujas langas)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Šaltinis‎: Ann N Y Acad Sci 2010;1202:158-64.

Kodas‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (atsiveria naujas langas)